Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för canagliflozin anhydrous. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2023-08-22

Design, Synthesis, and Biological Evaluation of Thioglucoside Analogues of Gliflozin as Potent New Gliflozin Drugs.

Feng GJ, Guo YF, Tang Y, Li M, Jia Y, Li Z, Wang S, Liu H, Wu Y, Dong H.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c01138

Bibliografisk träff 2023-07-19

A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.

Sutherland JJ, Yonchev D, Fekete A, Urban L.

Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-023-40064-9

Bibliografisk träff 2022-12-30

Mechanistic Insight of Synthesized 1,4-Dihydropyridines as an Antidiabetic Sword against Reactive Oxygen Species.

Sidhom PA, El-Bastawissy E, Ibrahim MAA, Shawky AM, Salama A, El-Moselhy T.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c01818

Bibliografisk träff 2020-01-29

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.9b01701

Bibliografisk träff 2019-10-12

Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.

Haider K, Pathak A, Rohilla A, Haider MR, Ahmad K, Yar MS.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2019.111773

Bibliografisk träff 2018-06-14

Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.

Li Z, Xu X, Deng L, Liao R, Liang R, Zhang B, Zhang L.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2018.06.017

Bibliografisk träff 2017-05-05

Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.

Li Y, Shi Z, Chen L, Zheng S, Li S, Xu B, Liu Z, Liu J, Deng C, Ye F.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.6b01818

Bibliografisk träff 2012-05-04

C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

Ohtake Y, Sato T, Matsuoka H, Kobayashi T, Nishimoto M, Taka N, Takano K, Yamamoto K, Ohmori M, Higuchi T, Murakata M, Morikawa K, Shimma N, Suzuki M, Hagita H, Ozawa K, Yamaguchi K, Kato M, Ikeda S.

Bioorg Med Chem · journal article · DOI 10.1016/j.bmc.2012.04.053